HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin

Figure 3 Frequency of hepatitis C virus-specific cell-mediated immune responses induced by CIGB-230 in combination with interferon-α plus ribavirin on week 48. A: Frequency of lymphoproliferative responses against hepatitis C virus (HCV) antigens. ^aDenotes a statistically significant difference between the CIGB-230 early add-on groups (E6 + E9) and the control group regarding the frequency of de novo core-specific responses (P = 0.04); B: Frequency of interferon-γ secretion responses against HCV antigens. ^aDenotes a statistically significant difference between L6 group and the control group with respect to the frequency of de novo core specific responses (P = 0.03). Significant differences were considered for P < 0.05; Fisher’s exact test. In the Figure “De novo positive” refers to responses that were undetectable on week 0 and became detectable on week 48; “Positive” refers to detectable responses on week 48 that were also detectable on week 0, and “Negative” refers to undetectable responses on week 48.